KITE: Parkinson's KinetiGraph as Tool for DBS Eligibility Assessment

Sponsor
MedtronicNeuro (Industry)
Overall Status
Completed
CT.gov ID
NCT02509325
Collaborator
(none)
38
2
7.1
19
2.7

Study Details

Study Description

Brief Summary

The purpose of the study is to investigate the feasibility of using the commercially available Parkinson's KinetiGraph Data Logger (PKG) to quantitatively assess motor fluctuations in Parkinson's Disease (PD) patients. A reliable and objective assessment of motor fluctuations would support the general neurologists in the referral of PD patients to the Deep Brain Stimulation (DBS) surgical centers and facilitate the DBS eligibility evaluation of PD patients usually done by the DBS specialists at the DBS surgical centers.

As part of the routine clinical practice, PD patients are referred to the DBS surgical center (clinical site) to optimize their PD treatment and potentially receive a DBS therapy, and the Principal Investigator (PI), a DBS specialist, assesses their DBS eligibility following published expert evaluation criteria and assigns the patient to one of the following two groups (PI assessment):

  1. DBS ready, if the patient presents severe motor fluctuations and/or clear dyskinesia history.

  2. DBS not-ready, if the patient presents neither severe motor fluctuations, nor clear dyskinesia history.

As part of routine clinical practice, the PKG responsible physician will provide the patient with the PKG to be worn for 6 to 10 days.

Based on the Global Kinetics Corporation (GKC) algorithm applied on the data recorded by the PKG, a GKC representative assigned the patients to one of the above mentioned groups: DBS ready or DBS not-ready.

The primary objective is to evaluate whether the GKC algorithm can differentiate DBS ready from DBS not-ready patients as assessed during the visit at the clinical site by the DBS specialist. The primary endpoint is therefore the percentage of agreement between the PI assessment and the GKC assessment (DBS ready or DBS not-ready) about the DBS eligibility of the PD patients.

Condition or Disease Intervention/Treatment Phase
  • Device: Parkinson's Kinetigraph

Study Design

Study Type:
Observational
Actual Enrollment :
38 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Evaluation of the Parkinson's KinetiGraph Data Logger (PKG) as a Tool to Measure Motor Fluctuations and Support the DBS Eligibility Assessment of Parkinson's Disease Patients.
Study Start Date :
Jul 1, 2015
Actual Primary Completion Date :
Feb 1, 2016
Actual Study Completion Date :
Feb 1, 2016

Outcome Measures

Primary Outcome Measures

  1. Percentage of agreement between the PI assessment and the GKC assessment to differentiate the DBS Ready (DS) from the DBS Not-Ready (DNR) group. [The PI assessment is performed during the examination of the patient by the DBS specialist on the first day of the study. The GKC assessment is calculated once the PKG is returned and it is based on the time period of 6 days of PKG recordings]

    The percentage of agreement is the number of patients in the Per Protocol (PP) set for which the GKC assessment is equal to the PI assessment, divided by the total number of patients in the Per Protocol (PP) set and multiplied by 100.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients are diagnosed with PD.

  • Patients are presented to the clinical sites to evaluate DBS candidacy or optimize their PD treatment eventually with DBS therapy.

  • Patients are at least 18 years old.

  • Patients are able to provide written data release consent as required by Ethics Committee (EC) institutions or local law and regulations.

Exclusion Criteria:
  • Patients have restricted movement, e.g. bed bound.

  • Patients operate heavy machinery for prolonged periods.

  • Patients have serious medical conditions that compromise safety or interfere with mobility in addition to PD (e.g. arthritis and rheumatisms).

  • Patients have been already screened by Stimulus or EarlyStimulus questionnaires

  • Patients present no response to Levodopa medication or have atypical Parkinsonism.

  • Patients have major medical or psychiatric illness other than stable, treated depression or anxiety that may jeopardize the patient's ability to give informed consent, follow study requirements, or that may confound the patient's diagnosis or assessments.

  • Patients have major neurological diagnoses other than PD.

  • Patients are not capable of following the required clinical instructions

Contacts and Locations

Locations

Site City State Country Postal Code
1 Centre Hospitalier Universitaire de Grenoble La Tronche France 38700
2 Universitätsklinikum Würzburg Würzburg Germany 97080

Sponsors and Collaborators

  • MedtronicNeuro

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
MedtronicNeuro
ClinicalTrials.gov Identifier:
NCT02509325
Other Study ID Numbers:
  • 1.01.8006
First Posted:
Jul 28, 2015
Last Update Posted:
Jan 26, 2022
Last Verified:
Jan 1, 2022
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 26, 2022